콘텐츠로 건너뛰기
Merck
  • Synoviolin/Hrd1, an E3 ubiquitin ligase, as a novel pathogenic factor for arthropathy.

Synoviolin/Hrd1, an E3 ubiquitin ligase, as a novel pathogenic factor for arthropathy.

Genes & development (2003-09-17)
Tetsuya Amano, Satoshi Yamasaki, Naoko Yagishita, Kaneyuki Tsuchimochi, Hiroshi Shin, Ko-ichi Kawahara, Satoko Aratani, Hidetoshi Fujita, Lei Zhang, Rie Ikeda, Ryoji Fujii, Naoki Miura, Setsuro Komiya, Kusuki Nishioka, Ikuro Maruyama, Akiyoshi Fukamizu, Toshihiro Nakajima
초록

Rheumatoid arthritis (RA) is one of the most critical articular diseases with synovial hyperplasia followed by impairment of quality of life. However, the mechanism(s) that regulates synovial cell outgrowth is not fully understood. To clarify its mechanism(s), we carried out immunoscreening by using antirheumatoid synovial cell antibody and identified and cloned "Synoviolin/Hrd1", an E3 ubiquitin ligase. Synoviolin/Hrd1 was highly expressed in the rheumatoid synovium, and mice overexpressing this enzyme developed spontaneous arthropathy. Conversely, synoviolin/hrd1(+/-) mice were resistant to collagen-induced arthritis by enhanced apoptosis of synovial cells. We conclude that Synoviolin/Hrd1 is a novel causative factor for arthropathy by triggering synovial cell outgrowth through its antiapoptotic effects. Our findings provide a new pathogenetic model of RA and suggest that Synoviolin/Hrd1 could be targeted as a therapeutic strategy for RA.